Mibefradil-induced inhibition of proliferation of human peripheral blood mononuclear cells

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 4, 1999, Pages 595-604

  Lijnen, P ^a,b   Fagard, R ^a   Petrov, V ^a  

^a KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Calcium; Mibefradil; Mononuclear cells; Proliferation

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 3,4,5 TRIMETHOXYBENZOIC ACID 8 (DIETHYLAMINO)OCTYL ESTER; CALCIUM; CALCIUM ANTAGONIST; CONCANAVALIN A; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MIBEFRADIL; NIFEDIPINE;

ADULT; ARTICLE; CALCIUM TRANSPORT; CELL COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DNA SYNTHESIS; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0032956821     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199904000-00012     Document Type: Article

References (36)

1. Lichtman AH, Segel GB, Lichtmann MA. The role of calcium in lymphocyte proliferation. Blood 1983;81:413-22.
2. Whitney RB, Sutherland RM. Requirement for calcium ions in lymphocyte transformation stimulated by phytohemagglutin. J Cell Physiol 1972;80:329-37.
3. Kay JE. Interaction of lymphocytes and phytohaemagglutinin: inhibition by chelating agents. Cell Res 1971;68:11-6.
4. Allwood G, Asherson GL, Davey MJ, Goodford PJ. The early uptake of radioactive calcium by human lymphocytes treated with phytohaemagglutinin. Immunology 1971;21:509-16.
5. Whitney RB, Sutherland RM. Enhanced uptake of calcium by transforming lymphocytes. Cell Immunol 1972;5:137-47.
6. Parker CW. Correlation between mitogenicity and stimulation of calcium uptake in human lymphocytes. Biochem Biophys Res Commun 1974;61:1180-6.
7. Luckasen JR, White JG, Kersey JH. Mitogenic properties of a calcium ionophore A23187. Proc Natl Acad Sci U S A 1974;71:5088-90.
8. Bühler FR, Fleckenstein-Grün G. A new class of calcium antagonists: from molecular biology to clinical benefit. J Cardiovasc Pharmacol 1996;27:S1-26.
9. Oparil S, Kobrin I, Abernethy DR, Levine BS, Reif MC, Shepherd AM. Dose-response characteristics of mibefradil: a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens 1997;10:735-42.
10. Viskoper RJ, Bernink PJLM, Schelling A, et al. A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. J Hum Hypertens 1997;11:387-93.
11. 2+ channel in cardiac tissue. Eur J Pharmacol 1995;290:155-8.
12. 2+ channels by Ro 40-5967. Circ Res 1994;75:144-8.
13. Lijnen P, Saavedra A, Petrov V. In vitro proliferative response of human peripheral blood mononuclear cells to concanavalin A. Clin Chim Acta 1997;264:91-101.
14. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cyctotoxicity. J Immunol Methods 1983;64:313-20.
15. Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995;272:399-406.
16. Gillies RJ, Diedier N, Denton M. Determination of cell number in monolayer cultures. Anal Biochem 1986;159:109-13.
17. Janossy G, Amlot P. Immunofluorescence and immunochemistry. In: Klaus CGB, ed. Lymphocytes: a practical approach. Oxford: IRL Press, 1987:67-108.
18. Schmitt R, Clozel JP, Iberg N, Bühler FR. Mibefradil prevents neointima formation after vascular injury in rats. Arterioscler Thromb Vasc Biol 1995;15:1161-5.
19. Herembert T, Zhu DL, Marche P. Mechanism of action of the inhibitory effect of nifedipine on the growth of cultured aortic cells from spontaneously hypertensive and normotensive rats. Br J Pharmacol 1995;114:1703-9.
20. Jackson CL, Schwartz SM. Pharmacology of smooth muscle replication. Hypertension 1992;20:713-36.
21. Uehara Y, Kawabata Y, Hirawa N, et al. OPC-13340: a new dihydropyridine calcium channel blocker attenuates rapid vascular smooth muscle cells growth in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992;20:408-15.
22. Witkowski JM, Siebert J, Lukaszuk K, Trawicka L. Comparison of the effect of a panel of membrane channel blockers on the proliferative, cytotoxic and cytoadherence abilities of human peripheral blood lymphocytes. Immunopharmacology 1993;26:53-63.
23. 2+ antagonist, 8-(N,N-diethylamino)-octyl-3,4,5-trimethoxybenzoate hydrochloride (TMB-8): studies in smooth muscles. Eur J Pharmacol 1974;27:25-33.
24. Jackson CL, Bush RC, Bowyer DE. Mechanism of antiatherogenic action of calcium antagonism. Atherosclerosis 1989;80:17-26.
25. Overturf M. Are calcium ion antagonists effective anti-atherogenic agents? Arteriosclerosis 1990;10:961-2.
26. Corcos T, David PR, Guiteras P, Reukin J, Dangaisse V, Rapold HG. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1985;109:926-31.
27. Lichtlen RR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1996;535: 1659-63.
28. El-Sanadiki MN, Cross S, Murray JJ, et al. Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment. Ann Surg 1996;212:87-96.
29. Pelisson-Guyotat I, Guyotat J, Lievre M, Chignier E. Effect of nimodipine on subintimal hyperplasia of autologous vein bypass grafts in rats: a placebo-controlled study. J Cardiovasc Pharmacol 1991;17:778-85.
30. Smith KA, Wang H-M, Cantrell D. The variables regulating T-cell growth. In: Yamamura VY, Tada T, eds. Progress in immunology V. New York: Academic Press, 1984:259-70.
31. Mills GB, Cheung RK, Grinstein S, Gelfand EW. Increase in cytosolic free calcium concentration is an intracellular messenger for the production of interleukin-2 but not for expression of the interleukin-2 receptor. Immunology 1985;134:1640-3.
32. Mills GB, Cheung RK, Grinstein S, Gelfand EW. Interleukin-2-induced lymphocyte proliferation is independent of increases in cytosolic free calcium concentration. Immunology 1985;134: 2431-5.
33. Gelfand EW, Cheung RK, Grinstein S, Mills GB. Characterization of the role of calcium influx in mitogen-induced triggering of human T-cells: identification of calcium-dependent and calcium-independent signals. Eur J Immunol 1986;16:907-12.
34. Morgano A, Pierri I, Stagnaro R, Setti M, Puppo F, Indiveri F. Decreased lymphocyte blastogenesis, IL-2 production and NK activity following nifedipine administration to healthy humans. Eur J Clin Pharmacol 1990;39:545-50.
35. Robb RJ, Greene WC, Rusk CM. Low and high affinity cellular receptors for interleukin-2: implications for the level of Tac antigens. J Exp Med 1984;160:1126-46.
36. Smith KA, Cantrell DA. Interleukin-2 regulates its own receptors. Proc Natl Acad Sci U S A 1985;82:864-8.